Our research into prostate cancer
Our strategy
For the past 120 years, we’ve been making discoveries that have saved countless lives. But we have so much more to do. Our strategy sets out how we'll accelerate progress towards a better future.
Our research is saving lives
Prostate cancer is the most common cancer in men in the UK, but more than 8 in 10 (84%) of patients now survive their disease for 10 years or more. We are at the heart of this progress – playing pivotal roles in the development of treatments like abiraterone and intensity modulated radiotherapy.
Current research
From studying the biology of prostate cancer cells in the lab to leading clinical trials testing cutting-edge treatments, our researchers are working hard to ensure more men survive prostate cancer.
Past research
Thanks to research, we've helped change the outlook for men with prostate cancer.
Patients' stories
Meet people like Alfred who have experienced first-hand how our research is making a difference. The life-saving research we do wouldn’t be possible without your support.
Cancer news
From cutting edge science and debunking myths to patient stories, read the latest news, analysis and opinion on our news site.
Further information
Our strategy to beat cancer sooner
Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just 1 in 4 people survived their disease for 10 years or more. Today 2 in 4 survive.
We want to accelerate progress and see 3 in 4 patients surviving the disease by 2034.